Why Hims & Hers Health Stock Is Falling - Hims & Hers Health ( NYSE:HIMS )
Eli Lilly and Co LLY today announced an expansion in the availability of its obesity treatment, Zepbound ( tirzepatide ) , which is now offered in 2.5 mg and 5 mg single-dose vials at a discounted price.
| Ticker |
Sentiment |
Impact |
|
LLY
|
Neutral
|
15 %
|
|
HIMS
|
Neutral
|
30 %
|
